IDEXX Laboratories Inc. (IDXX) Shows Resilience as Analysts Reassess Targets
IDEXX Laboratories Inc. (NASDAQ:IDXX) is one of the best medical technology stocks to invest in. On February 3, BTIG lowered its price target on IDEXX Laboratories Inc. (NASDAQ:IDXX) to $800 from $830 and maintained a Buy rating. The firm cited concerns about IDEXX’s 2026 guidance despite robust Q4 2025 earnings performance.
IDEXX reported strong fourth-quarter results, with revenue of $1.09 billion, up 14% from last year and above analyst expectations of $1.072 billion. Earnings per share rose 18% to $3.08, beating the Street’s $2.93 estimate. The company remains highly profitable, with a 61.7% gross margin and a return on equity of 65% over the past 12 months.
The companion animal business, IDEXX’s core segment, grew 15% to $998 million, driven by strong instrument revenue of $58 million, up 76% year-over-year. Growth was supported by 1,940 InVueDx system placements, as well as strong demand for Catalyst and SediVue products. This continues IDEXX’s long-term trend of about 10% annual revenue growth and aligns with management’s strategy of share buybacks to boost shareholder value.
For 2026, IDEXX expects revenue of $4.63–$4.72 billion and EPS of $14.29–$14.80, with operating margins slightly improving to 32%–32.5%. BTIG noted a 200-basis-point drag from fewer pet visits, mainly from lower-income owners, but expects 4% price growth globally. The company also plans around 5,500 new InVueDx system placements next year, compared with 6,400 in 2025, to help offset these headwinds.
IDEXX Laboratories Inc. (NASDAQ:IDXX) develops, manufactures, and distributes diagnostic and information technology products for veterinary, livestock, poultry, dairy, and water testing markets. Its offerings include point-of-care diagnostic instruments, rapid assay test kits, veterinary reference laboratory services, and microbiological contaminant testing systems.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Japan Reportedly Plans to Double Defense Spending to 3.5% of GDP, Ministry of Defense Denies, Yet Japanese Bond Yields Hit 30-Year High
According to reports, Japanese defense officials have expressed their willingness to significantly increase defense spending during meetings with the United States. One proposal is to raise defense spending to 3.5% of GDP within ten years, while another, lower target is 3%. Japanese officials previously stated that this fiscal year's defense and related expenditures are approximately $68.8 billion, equivalent to about 1.9% of Japan's nominal GDP in 2022.
Besent Defends US Intervention to Buy Yen: Only "Symbolic" Funds Invested; Yen Appreciation Benefits US Exports and Treasury Market
U.S. Treasury Secretary Janet Yellen said on Tuesday that when the U.S. Treasury coordinated with Japan to purchase yen, only a "symbolic" amount of funds was used. She defended this rare intervention in the foreign exchange market.
Overnight US Stocks | Three Major Indexes Fall for Second Consecutive Day, 10-Year Treasury Yield Rises to Highest Level Since 2007, WTI Crude Oil Surges 4%
At the close, the Dow Jones fell 328.09 points, down 0.63%, to 52,093.10 points; the S&P 500 Index fell 34.25 points, down 0.45%, to 7,585.73 points; the Nasdaq fell 204.84 points, down 0.78%, to 25,981.57 points.
Interest rate decision to be announced soon; market betting on a 94% probability of a rate hike—if unchanged, it could become the biggest “dovish surprise” in over 30 years
As the Federal Reserve is set to announce its interest rate decision on Wednesday, bond traders have almost universally concluded that a rate hike will be the final outcome.
Crypto prices
More
